In the CAVEATT study, 33 patients with TC and thymoma type B3 treated with platinum-based chemotherapy are registered and received avelumab combined with axitinib (an oral VEGFR-1/2/3 kinase inhibitor) for the primary endpoint of ORR. The gene discussed is FLT1; the disease is thymoma type B3.